# Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM

> **NCT07570810** · NA · NOT_YET_RECRUITING · sponsor: **Shanghai Jiao Tong University School of Medicine** · enrollment: 30 (estimated)

## Conditions studied

- Type 2 Diabetes
- Obesity
- Non-alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** CS0159
- **DRUG:** CS0159 placebo
- **DRUG:** Semaglutide

## Key facts

- **NCT ID:** NCT07570810
- **Lead sponsor:** Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2026-11-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07570810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07570810, "Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07570810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*